Evidence map›Paper›PMID 41054958›Full record

ArticleCancer biology & medicine2025

Evaluation of the multiple HPV-based "screen and triage" algorithms in real-world settings of rural China.

Remila Rezhake, Guzhanuer Abuduxikuer, Guligeina Abudurexiti, Qian Zhuo, Kadeliya Muhetaer, Tangnuer Abulimiti, Yumei Ouyang, Wenyun Li, Jing Yang, Gulixian Tuerxun and 3 more

Abstract read
In one paragraph

Article in Cancer biology & medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Remila RezhakeXinjiang Cancer Center, Affiliated Cancer Hospital of Xinjiang Medical University, Urumqi 830000, China.
Guzhanuer AbuduxikuerXinjiang Cancer Center, Affiliated Cancer Hospital of Xinjiang Medical University, Urumqi 830000, China.
Guligeina AbudurexitiXinjiang Cancer Center, Affiliated Cancer Hospital of Xinjiang Medical University, Urumqi 830000, China.
Qian ZhuoXinjiang Cancer Center, Affiliated Cancer Hospital of Xinjiang Medical University, Urumqi 830000, China.
Kadeliya MuhetaerXinjiang Cancer Center, Affiliated Cancer Hospital of Xinjiang Medical University, Urumqi 830000, China.
Tangnuer AbulimitiXinjiang Cancer Center, Affiliated Cancer Hospital of Xinjiang Medical University, Urumqi 830000, China.
Yumei OuyangXinjiang Cancer Center, Affiliated Cancer Hospital of Xinjiang Medical University, Urumqi 830000, China.
Wenyun LiXinjiang Cancer Center, Affiliated Cancer Hospital of Xinjiang Medical University, Urumqi 830000, China.
Jing YangXinjiang Cancer Center, Affiliated Cancer Hospital of Xinjiang Medical University, Urumqi 830000, China.
Gulixian TuerxunXinjiang Cancer Center, Affiliated Cancer Hospital of Xinjiang Medical University, Urumqi 830000, China.
Fanghui ZhaoDepartment of Cancer Epidemiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Guzhalinuer AbuliziXinjiang Cancer Center, Affiliated Cancer Hospital of Xinjiang Medical University, Urumqi 830000, China.ORCID 0000-0002-4999-5796
Marc ArbynUnit Cancer Epidemiology, Belgian Cancer Centre, Sciensano, Brussels 1050, Belgium.

Funding

CAMS Innovation Fund for Medical Sciences CAMS 2021-I2M-1-004National Natural Science Foundation of China 72264038National Natural Science Foundation of China 82260660The Key Research and Development Program of Xinjiang Uygur Autonomous Region of China 2022B03019-2
6 · The paper itself

Abstract

objectiveDrawbacks of human papillomavirus (HPV) primary screening, including high referral rates and low specificity, highlight the necessity for triage strategies to balance the screening benefits with potential harms.

methodsA cross-sectional, population-based diagnostic study was conducted in rural Xinjiang, China involving 8,638 women ≥ 25 years of age who participated in organized cervical cancer screening between 2023 and 2024. The study evaluated the accuracy and efficiency of multiple HPV-based "screen-triage" strategies. Histologically confirmed cervical intraepithelial neoplasia grade 2 or worse (CIN2+ and CIN3+) served as disease outcomes.

resultsAmong single-step triage strategies, only extended genotyping for the seven most carcinogenic HPV types (HPV16/18/31/33/45/52/58) maintained sensitivity for CIN2+ comparable to HPV screening without triage (90.0%

conclusionsFocusing on the seven high-risk HPV types within a one-step "screen-triage" framework effectively balances minimal sensitivity loss with significant gains in specificity, reducing unnecessary referrals and treatments, especially valuable in resource-limited settings. Integrating HPV genotyping with methylation results improves the accurate identification of women requiring immediate referral, which is advisable when resources allow.

Indexed as

Early Detection of CancerPapillomaviridaePapillomavirus InfectionsTriageUterine Cervical DysplasiaUterine Cervical NeoplasmsAdultAgedAlgorithmsChinaColposcopyCross-Sectional StudiesFemaleHumansMiddle AgedRural PopulationCervical cancer screeningHPV genotypinghuman papillomavirus (HPV)methylationtriage

Identifiers

PMID41054958
PMCPMC12501896

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.